You are here
Professor Bruno Flamion
Editor Biosimilars Module 2
Bruno Flamion, MD/PhD from the University of Brussels, Brussels, Belgium, is a specialist in internal medicine. He obtained a PhD degree in physiology and was a research fellow at the National Institutes of Health in Bethesda, MD, USA (1988–1992) and at the Belgian National Fund for Scientific Research (1992–1996). He has been Full Professor of Physiology and Pharmacology at the University of Namur, Belgium, since 1998.
Professor Flamion was a medical and pharmacological expert for the Belgian Federal Agency for Medicines and Health Products (FAMHP) for 12 years and has worked for the European Medicines Agency (EMA) in London for 10 years, acting as the Belgian member of CHMP (Committee for Human Medicinal Products) and CAT (Committee for Advanced Therapies). He was also Vice Chair of the Pharmacogenomics Working Party, Chair of the Pharmacokinetics Group, and, most importantly, Chair of the Scientific Advice Working Party for 6 years (2005–2010), where he was in contact with most of the major drug development programmes including biosimilars.
Professor Flamion has also chaired the Committee for Reimbursement of Medicines (CTG/CRM) in Belgium (2010–2012). This committee is part of the National Institute for Health and Disability Insurance (INAMI/RIZIV). Bruno Flamion is now managing a consultancy called BFLAM sprl, located in Belgium. His interests lie in clinical pharmacology, drug development (both regulatory and health technology assessment/reimbursement aspects), patient care, and basic research.